Repligen (RGEN) Misses Q1 Earnings Estimates
Yahoo Finance · 6 days ago
Open | 168.34 |
High | 169.21 |
Low | 165.99 |
Mkt Cap | 9.33B |
P/E (TTM) | 618.74 |
Div & Yield | N/A & N/A |
Prev. Close | 168.04 |
52 Wk. Low | 110.45 |
52 Wk. High | 211.13 |
Related stocks
BioTech Company
Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and was incorporated in Delaware in 1981. Wikipedia
(USD) | Q1 2024 | Y/Y |
---|---|---|
Revenue | 151.35M | 17.10% ▼ |
Net Income | 2.09M | 92.70% ▼ |
Diluted EPS | 0.28 | 92.60% ▼ |
Quarter | EPS Estimate | EPS Actual |
---|---|---|
Q2 2024 | $0.33 | - |
Q1 2024 | $0.30 | $0.28 |
Q4 2023 | $0.33 | $0.33 |
S&P 500^GSPC | 5,192.46+11.72 (+0.23%) |
Dow 30^DJI | 38,952.81+100.54 (+0.26%) |
Nasdaq^IXIC | 16,362.28+13.03 (+0.08%) |
105.16-9.71% | |
10.56+2.18% | |
Datadog, Inc.DDOG | 114.36-9.93% |